Published

March 7, 2025

Atezolizumab in combination with carboplatin and etoposide [ATE7]

For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met:

  1. This application is being made by and the first cycle of systemic anti -cancer therapy with atezolizumab in combination with carboplatin and etoposide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
  2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies, hepatitis and skin toxicity.
  3. The patient has a histologically or cytologically determined diagnosis of small cell lung cancer (SCLC).
  4. The patient has been staged as having extensive stage small cell lung cancer.
  5. The patient has not received previous systemic therapy for his/her extensive stage disease. Previous treatment with concurrent chemoradiotherapy for limited stage SCLC is allowed as long as therapy was completed at least 6 months prior to the diagnosis of recurrent and extensive stage disease.
  6. The patient has an ECOG performance status score of 0 or 1.
  7. The patient will be treated with a maximum of four 3-weekly cycles of atezolizumab in combination with carboplatin (AUC 5mg/ml/min) and etoposide (100mg/m² IV on days 1-3 or oral equivalent on days 2-3).
  8. On completion of 4 cycles of atezolizumab in combination with carboplatin and etoposide and in the absence of disease progression, treatment with atezolizumab maintenance monotherapy will continue until disease progression or symptomatic deterioration or unacceptable toxicity or withdrawal of patient consent, whichever occurs first.
  9. Atezolizumab will be administered either subcutaneously at a dose of 1875mg every 3 weeks or intravenously at a dose of 1200mg every 3 weeks or 1680 mg every 4 weeks.
  10. The patient has no symptomatically active brain metastases or leptomeningeal metastases.
  11. The patient has had no prior treatment with anti-PD-L1/PD-1 therapy for small cell lung cancer.
  12. A formal medical review as to how treatment with atezolizumab in combination with carboplatin plus etoposide is being tolerated and whether treatment with atezolizumab plus chemotherapy should continue or not will be scheduled to occur at least by the end of the first 6 weeks of treatment
  13. Where treatment break of more than 12 weeks beyond the expected 3-weekly or 4-weekly cycle length is needed, I confirm that I will complete a treatment break approval form to restart treatment.
  14. Atezolizumab, carboplatin and etoposide will be otherwise used as set out in their respective Summary of Product Characteristics (SPCs).

NHS funded From: 31 July 2020

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA638 (01 July 2020)

Current Form Version

Note

The data on this page was produced using version 1.353 of the CDF list, downloaded from an archive of NHS England’s website on 07 March 2025 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.